Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Stage I-III Limited Disease Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Official Title

A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients With Stage I-III Limited Disease Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)

Summary:

This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I-III LD-SCLC Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Trial Description

Primary Outcome:

  • Progression-free survival (PFS)
  • Overall Survival (OS)
Secondary Outcome:
  • Overall Survival (OS)
  • Objective Response Rate (ORR)
  • Progression-free survival PFS
  • Progression-free survival at 18 months (PFS18)
  • Progression-free survival at 24 months (PFS24)
  • Time to death or distant metastasis (TTDM)
  • Proportion of patients alive at 24 months (OS24)
  • Proportion of patients alive at and 36 months (OS36)
  • Time from randomization to second progression (PFS2)
  • To assess symptoms and health-related QoL in patients treated withdurvalumab or durvalumab and tremelimumab combination therapy compared to placebo using the EORTC QLQ-C30 v3
  • To assess the PK of durvalumab and tremelimumab in blood (peak trough concentration)
  • Presence of anti-drug antibodies (ADA) for durvalumab and tremelimumab (confirmatory results: positive or negative)
  • To assess a relationship between a tumour mutational burden (TMB) measured as biomarker presence in tumour and/or blood and Progression-free survival (PFS) with durvalumab and durvalumab and tremelimumab combination therapy
  • To assess symptoms and health-related QoL in patients treated withdurvalumab or durvalumab and tremelimumab combination therapy compared to placebo using the EORTC QLQ-LC13
  • To assess a relationship between a tumour mutational burden (TMB) measured as biomarker presence in tumour and/or blood and Objective Response Rate (ORR) with durvalumab and durvalumab and tremelimumab combination therapy
  • To assess a relationship between a tumour mutational burden (TMB) measured as biomarker presence in tumour and/or blood and Overall Survival (OS) with durvalumab and durvalumab and tremelimumab combination therapy

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society